Objective
Brain disorders affect ~179 million people and their families in Europe alone, with an annual cost to the taxpayer estimated at €800 billion- a greater economic burden than cardiovascular disease and cancer combined. Despite diverse etiology, overlap in clinical symptoms and comorbidities between brain disorders suggests shared patho-mechanisms. In particular, hyperexcitible states driven by glial activation and neuroinflammation appear near ubiquitous. Targeting these mechanisms offers the potential to ameliorate symptoms and reverse disease progression across a broad span of brain disorders. Functioning as a gatekeeper to neuroinflammation and mechanistic link between neuronal hyperexcitability and glial activation, the ATP-gated, ionotropic purinergic P2X7 receptor (P2X7R) offers the most promising target for pharmacological intervention in the neuroinflammation-hyperexcitability pathway, to date. With breakthroughs in understanding P2X7R function, highly promising effects demonstrated for antagonists in models of brain disease and vast investment in P2X7R-related drug development programmes, now is the perfect time to pool resources. PurinesDX brings together global leaders in translational research in purinergic signalling, Europe’s leading clinical specialists in a broad range of brain diseases, and industrial partners specializing in drug and biomarker development. Sharing unique genetic tools, newly developed diagnostic devices and novel, selective and brain-stable P2X7R antagonists, the synergism facilitated within PurinesDX will extend to the training of an urgently needed new generation of highly skilled, innovative, creative and entrepreneurial scientists. Alongside the provision of this interdisciplinary, international and intersectoral environment, an original and high level training in state-of-the-art neuroscience will be provided, nurturing a cohort of highly competitive researchers with potential to drive a new era of neuroscience research.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicineneurologyepilepsy
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health sciencesbasic medicineneurologyamyotrophic lateral sclerosis
Programme(s)
Funding Scheme
MSCA-ITN-ETN - European Training NetworksCoordinator
2 Dublin
Ireland
See on map
Participants (8)
80539 MUNCHEN
See on map
28040 Madrid
See on map
1083 Budapest
See on map
80539 Munchen
See on map
41013 Sevilla
See on map
Participation ended
MK40 3JY BEDFORD
See on map
2100 Goedoello
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
28049 MADRID
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partners (12)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
2340 Beerse
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
Dortmund
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
53227 Bonn
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
D24 X095 Dublin
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
28029 MADRID
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
28034 Madrid
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
1085 Budapest
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
Frankfurt Rhein-Main
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
80539 MUENCHEN
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
CV4 8UW COVENTRY
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
28049 Madrid
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
2100 Godollo
See on map